MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that MoonLake Immunotherapeutics Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against MoonLake Immunotherapeutics for alleged violations of federal securities laws, claiming that the company made false statements regarding the efficacy of its drug candidate, sonelokimab [1][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased MoonLake securities between March 10, 2024, and September 29, 2025 [2]. - Allegations include that MoonLake misrepresented the efficacy of sonelokimab, claiming it was superior to other monoclonal antibodies without evidence [3]. - The Phase 3 trial results of sonelokimab were described as "disastrous," leading to a nearly 90% loss in the company's stock value [3]. Group 2: Next Steps - Investors who suffered losses in MoonLake have until December 15, 2025, to request to be appointed as lead plaintiff in the class action [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if successful in the lawsuit [5]. - Bronstein, Gewirtz & Grossman, LLC has a history of recovering hundreds of millions of dollars for investors in securities fraud cases [6].